57680-56-5
Chemical Structure
Sucrose octasulfate
- CAS No.: 57680-56-5
- Formula:C12H22O35S8
- Molecular Weight:982.80
InChIKey: WEPNHBQBLCNOBB-UGDNZRGBSA-N
SMILES: O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)(O)=O
Biological Activity: Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sucrose octasulfate | Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. [Content Brief]
- [2]. Dissemond J, et al. Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden [Sucrose octasulfate-evidence in the treatment of chronic wounds]. Hautarzt. 2020 Oct;71(10):791-801. German. [Content Brief]
- [3]. Lucey MR, et al. Sucrose octasulfate stimulates gastric somatostatin release. Am J Med. 1991 Aug 8;91(2A):52S-57S. [Content Brief]
Keywords
